Evotec SE (Evotec) is a provider of drug discovery and development solutions. The company works in partnership with pharmaceutical companies, small and large biotechnology companies, patient advocacy groups and academic institutions for the discovery and development of pharmaceutical products. It offers solutions ranging from early target identification to manufacturing of compounds and commercial products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D focuses on developing drug discovery programs through its in-house R&D capabilities, in partnership with pharmaceutical companies, small and large biotechnology companies, patient advocacy groups and academic institutions. Its R&D encompasses therapy areas including immunology, fibrosis, gynaecology, respiratory, neurology, oncology, kidney, pain, inflammation and rare diseases. As of December 31, 2022, Evotec had over 60 patent families and pipeline of about 130 partnered projects and 60 unpartnered projects under various stages of development. The major in-house and partnered projects under development include EVT201 in Phase III for insomnia; eliapixant in partnership with Bayer in Phase II clinical trials indicated for the treatment of chronic cough, overactive bladder, neuropathic pain and endometriosis; CT7001 in partnership with Carrick in Phase II for oncology; and EVT894 in partnership with Sanofi in Phase I for chikungunya. The company also has partnership with companies with Bristol Myers Squibb. In FY2022, the company spent EUR76.6 million on its R&D, which as a percentage of revenue stood at 10.2%.